Merck & Co. Inc., of Kenilworth, N.J., said the FDA expanded the label for Keytruda (pembrolizumab), in a fixed dose of 200 mg every three weeks, to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.